

Thank you very much for the review, below we detail the point-to-point feedback of the reviewers.

*Reviewer 1:*

Thank you very much for your review and the comment of minor changes.

We have reviewed the attached document in which we do not see any proposed change in the manuscript. We understand that it has been an error, if you could send us the changes, we will review them and make them as soon as possible.

*Reviewer 2:*

First of all, thank you very much for the comments and the positive review with minimal changes, below we detail response by response to all the comments provided.

*“1. there has been few similar manuscripts published before, authors should cite atleast one of them and suggest how their paper is different. e.g previously similar articles of treatment reviews are published but we review updated literature with focus on articles published in high impact journals. one similar article you can consider citing is (Boregowda U, Gandhi D, Jain N, Khanna K, Gupta N. Comprehensive Literature Review and Evidence evaluation of Experimental Treatment in COVID 19 Contagion. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. January 2020. doi:10.1177/1179548420964140)”*

It is true that there are more articles published that encompass the treatment but we believe that this is one of the most up-to-date and that most graphically reveals the appropriate time for the start of each one of them.

However, we add the bibliographic reference provided to our text.

*“2. In my opinion any article that discuss COVID-19 treatments should atleast have small paragraph under section of anticoagulation, mentioning role of anticoagulation in patients hospitalized with COVID-19. almost all institution in US recommend prophylactic dose enoxaparin in all patients if bleeding risk is acceptable even if they are young and ambulatory not only from prevention of VTE perspective but it has somewhat beneficial effect on what is described as thromboinflammatory state . one article that summarize this in general is (Skeik N, Smith JE, Patel L, Mirza AK, Manunga JM, Beddow D. Risk and Management of Venous Thromboembolism in Patients with COVID-19. Ann Vasc Surg. 2021 Feb 10:S0890-5096(20)31039-6. doi: 10.1016/j.avsg.2020.11.007. Epub ahead of print. PMID: 33333197; PMCID: PMC7834325)”*

*This article aims to analyze the evidence available so far for drugs aimed at the direct treatment of COVID19 infection, both in the viral replication phase and in the inflammatory phase.*

*In our opinion, anticoagulation treatment in these patients is secondary to the disease, and its clear role is still not very clear, as there are articles that speak in favor of prophylaxis and others of anticoagulant treatment. However, paying attention to your opinion as an expert, we have proceeded to introduce a small paragraph, with the recommended references in the text.*

## EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

### **(1) *Science editor:***

1 Scientific quality: The manuscript describes a Minireview of the comprehensive review of covid19 treatments. The topic is within the scope of the WJV.

(1) Classification: Grade A and Grade B;

(2) Summary of the Peer-Review Report: Overall very well written manuscript, easy to read and well organized for practicing clinicians. Authors should mention the role of anticoagulation in patients hospitalized with COVID-19. The questions raised by the reviewers should be answered;

(3) Format: There are 2 tables and 1 figures;

(4) References: A total of 47 references are cited, including 42 references published in the last 3 years;

(5) Self-cited references: There is no self-cited reference; and

(6) References recommendations (kindly remind): The authors have the right to refuse to cite improper references recommended by the peer reviewer(s), especially references published by the peer reviewer(s) him/herself (themselves). If the authors find the peer reviewer(s) request for the authors to cite improper references published by him/herself (themselves), please send the peer reviewer's ID number to [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com). The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately.

2 Language evaluation: Classification: Grade A and Grade B. The manuscript is reviewed by a Scientific and Literary English translator.

3 Academic norms and rules: No academic misconduct was found in the Bing search.

4 Supplementary comments: This is an invited manuscript. No financial support was obtained for the study. The topic has not previously been published in the WJV.

5 Issues raised:

(1) Please provide the manuscript in MS Word format;

(2) The contributions of each author must be listed according to the order of authorship. The 'Author contributions' passage describes the specific contribution(s) made by each author;

(3) The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor; We are sorry to say that our pictures and tables are original so we cannot provide other documents.

(4) PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout; and We are sorry about this failure, we have reviewed all of them, so this problem must be solved.

(5) Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, "Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. Our pictures and tables are original.

[6]". And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable. Our pictures and tables are original.

6 Recommendation: Conditional acceptance.

**(2) Editorial office director:**

**(3) Company editor-in-chief:** I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Virology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors.